Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Actavis formally notifies Croatian regulator of Pliva bid
Actavis needs to gain approval from the Croatian financial authorities in order to proceed with its takeover bid. Actavis has submitted a proposal to pay Pliva shareholders a
Actavis needs to gain approval from the Croatian financial authorities in order to proceed with its takeover bid. Actavis has submitted a proposal to pay Pliva shareholders a
Under the agreement, the companies will initiate two parallel programs. One of these will evaluate a combination of Crestor with Abbott’s already marketed fibrate TriCor, while the other
A protein anti-angiogenic agent is already approved by the FDA for clinical use. However, the new compounds developed by the university researchers are small molecules rather than proteins,
Boots Group and Alliance UniChem announced plans in October 2005 to create Alliance Boots, an international pharmacy-led healthcare group. Alliance investors will now receive 1.332 new Boots shares
The alliance combines Origenis’ compound design and synthesis capabilities with Alcon’s applied biology expertise, screening capabilities and development expertise. Origenis will apply its technology platform MOREsystem to deliver
According to Dov, the reorganization is designed to maximize the value of the biopharmaceutical company’s existing pipeline and explore and pursue what it describes as “attractive financing opportunities.”
The data, published in the Journal of Clinical Oncology, demonstrated a median time to disease progression (TTP) for the 31 evaluable patients in the trial of 13.5 months.
The scientists at the University of Florida’s McKnight Brain Institute observed that when embryonic stem cells from mice were plated on four different surfaces in cell culture dishes,
Post-operative atrial fibrillation (AF) is the most common complication associated with the approximately 500,000 coronary artery bypass grafting and cardiac valve replacement surgeries performed each year. The company’s
ABIO 08/01 is the first in a new class of non-addictive drugs, different from anxiolytic sedatives, and is being developed to treat clinical anxiety states such as panic